NCT06771674 2025-09-09
Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma
Hookipa Biotech GmbH
Completed
Hookipa Biotech GmbH
Commonwealth Healthcare Corporation
University of California, San Diego
Nanfang Hospital, Southern Medical University
ChineseAMS